科研之友
微信
新浪微博
Facebook
分享链接
摘要
Aim To observe the effects of sacubitril/valsartan (Sac/Val, LCZ696) on atrial remodeling and atrial fibrillation (AF) susceptibility in spontaneously hypertensive rats (SHR). Methods Twenty-four 7-week-old male SHR were randomly divided into SHR group, SHR + Val group (30 mg · kg-1· d-1) and SHR + Sac/Val group (60 mg · kg-1· d-1), treated with valsartan or sacubitril/valsartan respectively. Eight Wistar rats were used as the control group. Rapid atrial pacing was used to observe the electrophysiological characteristics of atrium and the atrial fibrillation inducibility in SHR. Western blot was used to detect the expression of RAS and fibrosis related proteins. Results Compared with Wistar rats, the incidence of atrial fibrillation in SHR group significantly increased (P < 0. 05): ACE-1 and angiotensin protein expression were significantly up-regulated (P <0. 05), while ACE2 expression was down-regulated (P < 0.05) in atrial tissues of SHR; CollAl, CoBAl, TGF-β, and MMP9 were all significantly up-regulated in atrial tissues of SHR (P < 0. 05). Both valsartan and sacubitril/valsartan could significantly reduce the onset of atrial fibrillation, inhibit RAS related proteins and reverse atrial fibrosis. Moreover, the improvement effect of SHR + Sac/Val group was more obvious (P < 0. 05). Conclusions Both valsartan and sacubitril/valsartan can improve left atrial fibrosis and reduce the susceptibility of atrial fibrillation by inhibiting RAS in SHR. The effect of sacubitril/valsartan is better than that of valsartan, which is expected to become a new treatment drug of atrial fibrillation. ? 2021 Publication Centre of Anhui Medical University.
- 单位
